Koyratty, Nadia
Mbuya, Mduduzi N. N.
Jones, Andrew D.
Schuster, Roseanne C.
Kordas, Katarzyna
Li, Chin-Shang
Tavengwa, Naume V.
Majo, Florence D.
Chasekwa, Bernard
Ntozini, Robert
Humphrey, Jean H.
Smith, Laura E.
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1021542, OPP1021542)
National Institutes of Health (2R01HD060338‐06, 2R01HD060338‐06)
Department for International Development
Wellcome Trust (093768/Z/10/Z, 108065/Z/15/Z, 203905/Z/16/Z)
UNICEF (PCA2017-0002)
Article History
Received: 18 April 2022
Accepted: 19 October 2022
First Online: 18 November 2022
Declarations
:
: The Medical Research Council of Zimbabwe (MRCZ) and the Institutional Review Board (IRB) of the Johns Hopkins Bloomberg School of Public Health reviewed and approved the SHINE trial protocol. Written informed consent was obtained from the participating women in the local spoken languages (Ndebele, Shona, and English). All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable
: The authors declare that they have no competing interests.